| Papers [1-15] of 100 :: [Page 1 of 7] | | Go to page : 1 2 3 4 5 6 7 —> | Search results on "PHARMACEUTICAL COMPANY INDUSTRY": |
|
|
Pharmaceutical Company and Industry Analysis, 2001.
A company analysis of Merck & Company, INC., a pharmaceutical company.
5,390 words (approx. 21.6 pages), 30 sources, $ 132.95
»
Click here to show/hide summary
Abstract
This paper analyzes pharmaceutical company, Merck & Company, INC., . The author provides a company profile and examines a number of issues such as: product marketing, service marketing, manufacturing, values and motives of the company.
From the Paper
"The pharmaceutical industry is one of the largest and most far reaching industries in our nation, and therefore is an industry that can neither be avoided nor ignored. The amount of money spent on healthcare is phenomenal ? representing 14 cents of every dollar of goods and services produced in the United States (Jhin, 1996). New drugs that emerged in the past decade proved to be extremely profitable, and with new advances in technology and faster drug approval rates, the outcome is clear ? more money plus better science equals more new drugs (Kleinke, 1998). "
| |
|
International Finance and Pharmaceutical Company, 2008.
A case study analysis of the financial and operating performance, as well as market performance of the Company, a fictional pharmaceutical company.
1,822 words (approx. 7.3 pages), 2 sources, APA, $ 58.95
»
Click here to show/hide summary
Abstract
This paper presents a policy statement by the Company, a fictional pharmaceutical company, that discusses concerns and expectations about market conditions in the coming year, which may impact the Company's operations and profitability. It provides a plan that may impact upon future financial and operating performance for the Company. It also looks at threats to the financial stability of the Company.
Table of Contents:
Pounds, Dollar, and Euros: Purchasing Power Parity
US Economy Strength and Expansion of R&D Capacity
German Competitor Introduction of Generic Detervin
Federal Reserve Interest Rates
Inflation Rate in Turkey Expected to be Very High
Price Volatility on the New York Stock Exchange
Interest Rates on Government Bonds in US and Germany
Conclusion
From the Paper
"The Company faces several challenges in the coming financial years, including managing subsidiary operations in a volatile and changing environment. The fact that much of the growth potential for the Company is found in its foreign subsidiaries implies that it will have to find ways to finance operations through local avenues increasingly going forward. As the strength of the British pound become diluted closer to historical norms over time, the growth in subsidiaries should allow to the Company to increase both its operating and profit performance. Therefore, the coming year should represent significant opportunities to positively impact future growth with management's efforts to capitalize on market challenges around the world."
| |
|
Pfizer Pharmaceutical Company, 2004.
An analysis of the marketing success of the Pfizer Pharmaceutical Company.
1,938 words (approx. 7.8 pages), 6 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
This paper examines how Pfizer is one of the most successful pharmaceutical companies in existence and how much, if not most, of Pfizer?s success is due to the corporation?s marketing genius, which is considered to be among the best in the industry. It looks at how Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company. It also explores how, unlike most large corporations, Pfizer draws revenue from a limited number of products.
Outline
Company Structure and Marketing Strategies
Marketing Strengths
Threats
From the Paper
"The marketing principles utilized by Pfizer guides every aspect of the corporation?s business. There are five main principles that are fundamental to Pfizer?s business practices. First, the work conducted by Pfizer is grounded in science. With solid clinical research as a foundation, Pfizer?s marketing group uses its credibility and knowledge to develop important relationships within the medical community. Second, Pfizer takes an integrated approach to its marketing strategies. Innovation is promoted through the encouragement of teamwork within and across marketing groups. This also allows Pfizer to respond flexibly and promptly to changes in the market."
| |
|
The Walgreen's Pharmaceutical Company, 2002.
Analysis of a marketing strategy for Walgreen's Pharmaceutical Company.
1,900 words (approx. 7.6 pages), 6 sources, $ 71.95
»
Click here to show/hide summary
Abstract
This paper examines the strategic implementation of a marketing strategy for the Walgreen's Pharmaceutical Company. The author states clear objectives, and discusses products, promotion, services offered, price strategy, and methods of maintaining strategic competence.
| |
|
Social Responsibility of Pharmaceutical Companies, 2004.
Study of the ethics of pharmaceutical companies when conducting business and promoting their products.
5,370 words (approx. 21.5 pages), 32 sources, MLA, $ 132.95
»
Click here to show/hide summary
Abstract
This paper addresses several questions concerning the ethical conduct of pharmaceutical companies. The paper considers whether doctors that sit on the boards of companies can be impartial when they make decisions to financially back research/drugs of the pharmaceutical company they represent, as well as what should be the corporate responsibility of the pharmaceutical companies. Also considered is whether pharmaceutical companies have systems in place to keep them ethically responsible and if advertising by pharmaceutical companies actually creates a demand for prescriptions when no need actually exists. Numerous graphs and tables are included.
From the Paper
"Indeed, one of the unique aspects of advertising prescription pharmaceuticals is the caveat ?Ask your doctor?. The consumer cannot go out and directly purchase the product (note that via the internet this is now possible), but traditionally must receive a physician?s endorsement by way of a prescription. The pharmaceutical industry uses this reasoning to defend its promotional tactics, claiming that because doctors ultimately authorize prescriptions the public is insulated from deceptive advertising. Yet research indicates that doctors are likely to prescribe drugs patients request under increasing pressure. Patients often insist on brand names over generic drugs, some of which are just as effective and less costly."
| |
|
Pharmaceutical Company Ethics: Profit Before People, 2001.
An examination of the ways in which the pharmaceutical industry manipulates the system, people and doctors in an effort to maximize their profits.
3,000 words (approx. 12.0 pages), 18 sources, MLA, $ 88.95
»
Click here to show/hide summary
Abstract
This paper takes an in depth look at the ways in which pharmaceutical companies unscrupulously put profit before people. Five of the main ways in which they do this that are discussed are; manipulation of research, undue influence over doctors prescribing practices, direct-to-consumer advertising, discrediting of their competitors pharmaceutical and natural alike, and investing only in profitable research. Each topic is discussed thoroughly with credible sources to back the data up.
From the Paper
"The pharmaceutical industry wants people to believe that their main goal is to help people. The Pharmaceutical Research and Manufacturers of America (PhRMA) has even begun airing feel-good commercials featuring people whose lives have been saved by medications. In reality, they spend billions of dollars every year to ensure their true purpose, maximum profit. Their influence begins in the research lab, where the sponsor, usually a pharmaceutical company with a huge financial stake in the findings, has more to say over how the study is conducted and what information is released then the actual investigators, leading some of the foremost medical journals in the world to fight back with strict guidelines. After the pharmaceutical companies get their products approved, they engage in a campaign of bribery to persuade doctors to prescribe their name brand, expensive drugs over their competitor's products. Not wanting to leave it up to the doctors alone to endorse their products, the pharmaceutical industry has started advertising directly to an unwitting populace, on television and in popular magazines. Pharmaceutical companies use their political power and vast economic resources to discredit and undermine non-drug treatment options for various diseases, particularly by attacking the burgeoning field of holistic medicine. Furthermore, the pharmaceutical companies have a long history of not investing in research that would lead to drugs for diseases that effect the world's poor, because there is little profit to be made in developing nations. Through various immoral practices, the pharmaceutical companies put profit ahead of the interests, health and safety of consumers. "
| |
|
Governments and Pharmaceutical Companies, 2007.
This paper presents a research proposal to explore the effects of a long-term customer relationship in the pharmaceutical field.
2,017 words (approx. 8.1 pages), 21 sources, MLA, $ 63.95
»
Click here to show/hide summary
Abstract
The paper proposes to research the effects of applying long-term customer relationships in the pharmaceutical field, by targeting the cities in the Gulf areas and particularly, within the Kuwait market. The paper discusses the competition between the brand name industries and the generic industries and looks at how the governments of the Gulf countries are forced to choose between the two companies. The paper examines the mistrust that has developed because of the irresponsible situations and actions from both the pharmaceutical companies and the governments.
Outline:
Abstract
Introduction
The Research Problem
The Problem Statement
The Research Questions
Research Objectives
Methodology
Operational and Research Methodology
Problems and Limitations
From the Paper
"The pharmaceutical industry is a major business worldwide. The largest industry is the weapons industry and the pharmaceutical industry follows right behind the weapons industry. The pharmaceutical industry is the world's second largest business in terms of its products and services. Each year, governments from all over the world spend millions of dollars in order to secure medications, various equipment and other products and services that their countries need in order to help their sick citizens and maintain the health of those who are not sick. In addition to the government's spending on the medication and supplies from large suppliers, there is another competition from within in regards to outside research companies who produce different products that are used for the same ailments. These other research companies are known as the generic industry."
| |
|
Shire Pharmaceuticals - A Company Assessment, 2008.
A well-illustrated assessment of the company, Shire PLC, which has operations world wide.
3,535 words (approx. 14.1 pages), 28 sources, APA, $ 99.95
»
Click here to show/hide summary
Abstract
The paper is an in-depth, fully comprehensive study on the Shire Pharmaceutical Company, concentrating on the issues of finance and accounting. Performances of all sections of the company are highlighted and well-illustrated with graphs and tables, which are easy to analyze and understand. An interesting feature of the paper is a FAQ section which addresses issues, particularly relevant to financial management.
Outline:
Introduction
Methodology
Financial accounting
Financial m
Management accounting
From the Paper
"For the analysis of the literature gathered, one of the main objectives has to be able to present the analyses in a direct and concise manner, utilizing graphic representations or interpretations to illustrate deductions. Whenever possible, the research referred to expert opinions as the foundation of analyses as well as prevailing opinions posted through internet discussions about Shire, the pharmaceutical industry and trends in the FTSE. Models, summaries or tables derived from independent research were also used to facilitate discussion in the construction of the research as well as in the research documentation itself.
The consolidation of insights regarding Shire was done through a process of collaboration which then followed verification through a review of the primary and secondary literature used at the beginning of the research. The final written paper is designed to informative and comprehensive however there was recognition that the study could not be as exhaustive because of limitations on the length of the paper. This is one of the main challenges for the research: considering the amount of information the research required, significant discretion was to be exercised on what was to be included or excluded in the paper."
| |
|
The Pharmaceutical Industry, 2004.
This paper is a research proposal to investigate the impact of Structure-Conduct-Performance (SCP) of two multi-national pharmaceutical companies, Abbott Laboratories and Baxter Corporation, in their U.S., Canadian, and Brazilian markets.
2,365 words (approx. 9.5 pages), 4 sources, APA, $ 72.95
»
Click here to show/hide summary
Abstract
This paper delineates the objectives of the study: (1) To determine the impact of the environment in which the organization operates by using the PESTLE and SWOT (Strengths-Weaknesses-Opportunity-Threats) analysis methods;, (2) to present a brief history of the companies and to evaluate the products manufactured and sold; (3) to understand the health care market, the impact of laws and regulations and the role of national and local governments; (4) to perform a Michael Porter?s five-force analysis; and (5) to investigate the role of SCP. The author relates that this thesis will be based on a literature review and secondary data collection. The paper stresses that this study will provide useful information to policy and decision makers in the industry.
Table of Contents
Introduction
Proposed Methodology
Reflections and Potential Obstacles
Conclusion
From the Paper
"Competition is very intense in the modern day organization. Companies are increasingly striving to differentiate their products and services in the market in order to gain higher profits and a greater market share. Portfolio management, product life cycle management, decision analysis and risk analysis are becoming some of the strategies that have to be used by managers and executives all over the world. For-profit organizations are investing a lot of money and human resources to help identify variables that can make their organizations competitive in their respective markets. Failure in managing any one variable can result in the overall failure of the organization."
| |
|
The Pharmaceutical Industry, 2005.
This paper discusses the economics of the pharmaceutical industry.
3,130 words (approx. 12.5 pages), 7 sources, APA, $ 91.95
»
Click here to show/hide summary
Abstract
This paper explains that the intellectual property embodied in a drug is an extremely valuable asset for a pharmaceutical company, and its continued protection is directly related to the company's long-term success or failure. The author points out that Pfizer, the leading pharmaceutical company, has three main business practices and goals, which have overcome successfully the uncertainty in drug development and competitive pressures: (1) Extraordinary portfolio management practices, (2) security of daily management of resources and (3) profitable research and development. The paper relates that, in 1984 Congress passed of the Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, which weakened patent law for pharmaceuticals making it easier for generic copies to enter the market.
Table of Contents
Intellectual Property
Risk and Resource Management
Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act
Food, Drug and Cosmetic Act
Amendments to the 1938 Food, Drug and Cosmetic Act
From the Paper
"As a result, a high average level of intellectual property protection is economically beneficial. The benefits of strong intellectual property protection are greater in the pharmaceutical industry than they are in other industries, because pharmaceutical firms rely more on patents to protect intellectual property than firms in other industries. When a drug becomes generic as the result of a lost patent, the price goes down, although the demand may remain the same. A less costly drug decreases profits for a pharmaceutical company, which in turn would use the additional profits to invest in their risk and development fund to search for new medicines and cures. Patent law gives pharmaceutical researchers the basic incentive to conduct research and discover new cures."
| |
|
Quality Management in the Pharmaceutical Industry, 2004.
Presents a literature review relating to the issue of total quality management (TQM) in the pharmaceutical industry.
2,267 words (approx. 9.1 pages), 17 sources, APA, $ 70.95
»
Click here to show/hide summary
Abstract
Good manufacturing practices (GMP) are considered part of the quality control system for companies producing pharmaceutical products. GMP principles aim to ensure the regular production for products that conform to the health standards required from regulatory bodies. GMP provides the general basics to determine the minimum acceptable requirements for the production at good products, covering all the activities related to the production process. This paper hypothesizes that, although ISO 9000 certification, which is the world-wide quality management and quality assurance standard, is not required for pharmaceutical companies, only those with a company culture mature and ethical enough to implement TQM successfully will be able to successfully implement GMP (industry-specific standard). There has been a great deal of confusion concerning whether being in compliance with the pharmaceutical GMP would successfully lead to obtaining ISO certification with minimum changes and costs, or whether achieving ISO certification is going to be a long and expensive road. This paper hypothesizes that the ultimate success of a company?s ISO program will not depend solely on how well-defined its quality system is, but rather its commitment to maintaining GMP.
From the Paper
"In general, this is mainly because the companies have not taken seriously enough the fact that TQM involves a cultural change for the organization. It creates a shift in power between boss and employee. Many managers, especially those who were inadequately trained, have seen employees as accessories to their jobs - as people to be told what to do. People who are disempowered often fail to take initiative in identifying process or sub-component faults. According to the laws of human nature, employees treated this way will leave a great deal of work to be handled by management. According to the theories of TQM, managers have to learn to support, encourage and listen."
| |
|
Pharmaceutical Industry, 2004.
An overview of the pharmaceutical industry from an international perspective.
1,024 words (approx. 4.1 pages), 8 sources, MLA, $ 36.95
»
Click here to show/hide summary
Abstract
This paper begins by providing an analysis of the pharmaceutical industry. It presents a summary profile of the dominant economic characteristics of the pharmaceutical industry and then analyzes the industry through Porter's Five Forces. This is followed by an identification of key industry trends in the pharmaceutical industry. It then applies these findings briefly to the pharmaceutical company called Merck Inc.
From the Paper
"Drug packaging demand is predicted to grow at a rate of 4.3 percent annually in the United States through 2006. According to the report by the Freedonia Group, ?Blister packaging will remain the top group based on strength in unit dose, compliance, clinical trial, high barrier and high visibility formats. Pouches and strip packs will compete with blister in unit dose. Prefillable inhalers and syringes will grow the fastest in market value? (Freedonia Group)."
| |
|
Pharmaceutical Industry, 2006.
This paper discusses how the pharmaceutical industry affects the U.S. economy.
1,140 words (approx. 4.6 pages), 8 sources, MLA, $ 39.95
»
Click here to show/hide summary
Abstract
In this article, the writer looks at the global growth of the pharmaceutical industry and at the important part it plays in the U.S. economy. The writer notes that the United States accounts for 46 percent of the world's pharmaceutical market. The writer discusses the volume and cost of prescriptions dispensed in the United States.
The fact that the pharmaceutical industry is one of the most dynamic and largest sectors in the U.S. economy is examined in this paper. Further, the writer looks at the biotechnology and research fields in this regard. The writer concludes by looking at the growth in employment within the pharmaceutical industry.
From the Paper
"In 1995, the total retail cost of the prescriptions dispensed in the United States advanced 13.9 percent to $64.6 billion, and in terms of prescription volume, the retail market grew 8.3 percent with 1,235,708,000 and 912,565,000 new and refill prescriptions, respectively, dispensed. The pharmaceutical industry continues to look for innovative ways to reach new customers, for according to the Task Force for Compliance of the National Pharmaceutical Council, "noncompliant patients cost the U.S. economy an estimated $100 billion yearly in lost productivity and extra medical costs, not to mention lost product sales." To target the problem of under use, the industry implements disease management programs, as well as patient-focused education and promotional programs."
| |
|
Pfizer, Inc. and the Pharmaceutical Industry, 2005.
This paper is a risk analysis of Pfizer, Inc. and the pharmaceutical industry including its direct competitors: Bayer AG, Merck & Co., Novartis AG, Abbott Labs and Eli Lilly.
2,175 words (approx. 8.7 pages), 7 sources, MLA, $ 67.95
»
Click here to show/hide summary
Abstract
This paper explains that Pfizer and all five of its direct competitors essentially face many of the same risks such as the tendency for the marketplace to discourage the use of new medicines because of their higher costs. The author points out that the safety of products and proper usage by consumers are always concerns as demonstrated by the problems facing Bayer and Merck and, now, potentially, by Pfizer with Celebrex. The paper concludes that Pfizer is unique from its competitors and remains the leading pharmaceutical company because of its effective risk and resource management of the company's extraordinary portfolio management practices, security of the day-to-day management of resources and its research and development.
From the Paper
"The third goal, corporate social responsibility, means putting people and communities first and preserving and protecting the environment. It also means being sensitive to the needs of Pfizer's colleagues, and evaluating the company from a critical point of view. Over the past four years, Pfizer has almost tripled in size, from about 45,000 colleagues worldwide to over 122,000. In 2003, Pfizer created a global corporate citizenship coordinating team. The goal of this group is to help unify Pfizer's approach to corporate citizenship across many countries and cultures, through membership in organizations that promote responsible business practices internationally. Some of the initiatives that have been explored are the reduction of carbon monoxide emissions and supplying global energy through cleaner sources. This final goal is a symbol of Pfizer's commitment to strengthen leadership and become more responsive."
| |
|
Sales Revenues and Profits in the Pharmaceutical Industry, 2002.
A comprehensive analysis of changes in sales revenues and profits in the U.S. pharmaceutical industry from 1980-2000. It includes several original graphs based on relevant statistics.
1,524 words (approx. 6.1 pages), 11 sources, APA, $ 50.95
»
Click here to show/hide summary
Abstract
This paper analyzes how changes in sales revenues and profits in the pharmaceutical industry are related to the business cycle with regards to the gross domestic product, consumer price index, and unemployment rate from 1980-2000. The following guidelines were followed: 1) analysis of the pharmaceutical industry and finding revenues and profits from the period of 1980-2000; 2) how revenues and profits in the industry varied over the period 1980-2000; 3) how the business cycle behaved over the period of 1980-2000; 4) variations in revenues and profits with swings in the business cycle and the juxtaposition of industry revenues and profits against the business cycle;and 5) strategies recommended for firms in the industry dealing with the business cycle. A summary is provided in the conclusion. Several original graphs are also included.
From the Paper
"One expert suggests the modern pharmaceutical industry began in the 19th century with the discovery of highly active medicinal compounds that could most efficiently be manufactured on a large scale. As these compounds replaced herbal medicines of earlier times, the occurrence and severity of such diseases as pernicious anemia, rheumatic fever, typhoid fever, lobar pneumonia, poliomyelitis, syphilis, and tuberculosis were greatly reduced. Pharmaceutical industry research has greatly aided medical progress; of the 66 most valuable drugs introduced since aspirin in 1899, 57 were discovered and then produced in industrial laboratories (Atherton, 2002). Today, the pharmaceutical industry is comprised of the processes, operations, and organizations engaged in development and manufacture of drugs and medications (Atherton, 2002). In the U.S., the pharmaceutical industry is followed by the Standard & Poor 500 (S&P 500)."
|
|
|
